This duality explains why two opposing but complementary strategies are being explored: (i) inhibiting H2S biosynthesis with CBS/CSE/3-MST blockers to deprive the tumor of its bioenergetic advantage and (ii) overloading the tumor with high-dose donors (e.g., rapid polysulfide releasers) that push intratumoral concentration into the cytotoxic range. Here, CBS is linked to neoplasm.